Campylobacter is not a niche pathogen. It causes more gastroenteritis cases in the UK each year than all other monitored foodborne bacteria combined — and 60–80% of infections trace back to raw chicken. A new study in PNAS, analysing nearly 2,800 bacterial genomes from 30 countries collected between 1979 and 2024, has now quantified how industrial poultry production is turbocharging the bacteria's evolution. The mechanism is straightforward and alarming. Before chickens were domesticated 5,000 years ago, campylobacter strains stayed tightly bound to individual bird species. As chicken numbers exploded — seven-fold since the 1960s to approximately 27 billion birds, now roughly 70% of all bird biomass on Earth — the sheer density of the global flock created unprecedented contact between strains from wild birds and farmed chickens. The result: an estimated 100-fold increase in inter-host strain transitions since 1900 compared to pre-domestication levels. More mixing means more hybridisation, and hybridisation is where novel pathogen traits emerge. The antimicrobial resistance angle compounds the risk. Antibiotics are routinely administered in industrial poultry systems — both to accelerate growth and to manage disease in densely packed sheds. The study identified genetic changes in circulating campylobacter strains associated with AMR adaptation to this environment. Some antibiotics previously effective against campylobacter infections are already no longer working. Prof Sam Sheppard of Oxford, the paper's senior author, is blunt: 'We can't continue to produce chickens at this huge capacity.' The efficiency argument for industrial chicken farming is real — it has delivered affordable animal protein at scale to billions of people. Global per capita meat supply has grown substantially since the 1960s alongside this expansion. But the externalities are being socialised. The cost of treating drug-resistant campylobacter infections, the long-term IBS burden on patients who cannot get antibiotics, and the surveillance infrastructure required to track evolving strains — none of this appears on the balance sheet of industrial poultry producers. The profit is privatised; the pathogen risk is public. The regulatory backdrop makes this worse. Advocacy group Communities Against Factory Farming notes that the UK government is looking to relax planning rules to permit more industrial poultry facilities — moving in precisely the opposite direction from what the science recommends. The 100-fold increase in strain exchange is a lagging indicator: the conditions that produced it are still accelerating. If the evolutionary cauldron keeps expanding, the question is not whether a more dangerous hybrid strain emerges, but when. The 20-year trajectory here is not speculative — it is the direct extrapolation of a trend already visible in the genomic record. Continued intensification of chicken production, combined with routine antibiotic use and no structural reform, produces a pathogen reservoir that is larger, more genetically diverse, and more drug-resistant than today's. The public health system bears the treatment costs; the farming industry captures the margin. That is the extraction dynamic in plain view.
